B-cell receptor specific for rabies virus glycoprotein (BCR-RVG) (BCR-RVG)

The B-cell receptor specific for rabies virus glycoprotein epitopes is a membrane-bound immunoglobulin complex on B lymphocytes that mediates the adaptive immune response to the rabies virus (Lyles & Rupprecht, 2007). It specifically recognizes the rabies virus glycoprotein (RVG), which is the primary surface antigen responsible for viral entry and the induction of neutralizing antibodies (WHO, 2023). Upon binding to RVG epitopes, the BCR initiates signaling pathways that lead to B-cell activation, clonal expansion, and differentiation into plasma cells (Müller et al., 2009). This receptor is the primary target of rabies vaccines, which aim to stimulate the production of high-affinity neutralizing antibodies to prevent the virus from reaching the central nervous system (CDC, 2024). The interaction between the BCR and RVG epitopes is critical for both pre-exposure and post-exposure prophylaxis, making it a central focus of vaccine and monoclonal antibody development (Faber et al., 2002). Monitoring the resulting antibody titers is the gold standard for evaluating the success of these therapeutic interventions (WHO, 2023). Furthermore, the affinity and specificity of these receptors determine the breadth of protection against different rabies virus variants (Dietzschold et al., 2005). Advances in understanding this receptor's interaction with RVG have led to the development of recombinant vaccines and highly potent human monoclonal antibodies (Bakker et al., 2005).

Other names

Rabies virus glycoprotein-specific B-cell receptorAnti-rabies glycoprotein BCRRVG-specific B-cell receptorRabies-specific B-cell receptor

Vaccines containing the rabies virus glycoprotein or inactivated virus particles bind to these specific B-cell receptors, triggering intracellular signaling cascades that lead to B-cell activation, somatic hypermutation, and differentiation into high-affinity antibody-secreting plasma cells and memory B cells (Müller et al., 2009; CDC, 2024).